A new pharmaceutical substance may be helpful in treating this pulmonary disease. Prof. Dr. Bernd Lamprecht, head of the Department of Internal Medicine with a focus on Pneumology, talks about "idiopathic pulmonary fibrosis". What can you tell us about the new compound, Garadacimab?
Prof. Dr. Bernd Lamprecht: Garadacimab is a new monoclonal antibody that blocks activated XII factor. Activated XII factor acts as an enzyme in the blood clotting system and also helps to produce bradykinin, an inflammatory mediator.

How exactly can you use Garadacimab to slow the disease’s progression?
Prof. Dr. Bernd Lamprecht: Inflammatory processes play a role in the progression of pulmonary fibrosis, as this inflammation leads to increasing scarring of the lung tissue. As Garadacimab can slow down the inflammatory process, we expect to see a positive effect when it comes to preventing the way pulmonary fibrosis progresses.

What kind of side effects need to be taken into account?
Univ. Prof. Dr. Bernd Lamprecht: Previous experience using Garadacimab for another condition has shown headaches and susceptibility to nose and throat to be rare side effects that need to be taken into account.

Given that this form of treatment is only available at 38 centers worldwide, Linz is fast becoming a magnet for those suffering from this condition. Can you confirm that?
Univ. Prof. Dr. Bernd Lamprecht: I wouldn't call it a magnet, but the university studies we offer expand on available treatment options for those who suffer from this rare condition – a condition that has a limited treatment options at the moment. It also deepens our understanding of the mechanisms behind the way pulmonary fibrosis progresses. The fact this involves both the JKU and the Kepler University Hospital is well warranted, as there is plenty of specialist expertise and enormous potential for research at this large center.